Lumateperone by Intra-Cellular Therapies Inc., has multiple mechanisms, such as that of a potent serotonin 5-HT2A receptor antagonist; a dopamine receptor phosphoprotein modulator (DPPM), acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor. It is currently under review by the United States Food and Drug Administration (USFDA) for the treatment of schizophrenia, and is in the Phase III stage of clinical development for the treatment of bipolar depression and agitation associated with dementia, including Alzheimer’s disease.
The report will include comprehensive insights about Lumateperone’s market launch. It will further include clinical trial analysis; strategic development details, such as collaborations, licensing, drug designations, and patent details. This report will also provide comprehensive insights upon how Lumateperone will evolve in the market as well as within its respective therapeutic class.